Authors
Latest:
Dr Davies on Addressing Global Gaps in Multiple Myeloma CareFaith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.
Latest:
Dr. Succaria on Targetable Immune Checkpoints in Head and Neck CancerFarah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses targetable immune checkpoints in head and neck squamous cell carcinoma.
Latest:
Wellsphere Blogger Flap Raises Questions about Content OwnershipIt started with an e-mail to thousands of health bloggers from Dr. Geoff Rutledge, Chief Medical Information Officer at the health website Wellsphere.
Latest:
Dr. Kosari on Antitumor Immunity in Small Cell Lung CancerFarhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.
Latest:
Dr Ravandi-Kashani on the FDA Approval of Luspatercept in MDSFarhad Ravandi-Kashani, MD, discusses the FDA approval of luspatercept in myelodysplastic syndrome.
Latest:
Dr. Ravandi on BiTE Antibody AMG 330 Data in Relapsed/Refractory AMLFarhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.
Latest:
Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR TrialFarhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.
Latest:
Dr Awan on Treatment Considerations With Pirtobrutinib in Hematologic MalignanciesFarrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Latest:
Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in DLBCLFarrukh Awan, MD, discuses the evolving role of bispecific antibodies in the treatment paradigm of diffuse large B-cell lymphoma.
Latest:
Dr. Cardoso on the Global mBC Vision 2025 Call-to-ActionFatima Cardoso, MD, coordinator, European School of Oncology Breast Cancer Program, Secretary General, European Organization for Research and Treatment of Cancer, director, Breast Unit, Champalimaud Clinical Cancer Center, discusses the Global mBC Vision 2025 Call-to-Action.
Latest:
Dr. Roila on Aprepitant for the Prevention of Cisplatin-Induced Delayed EmesisFausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.
Latest:
First Liver Transplant Surgery Performed in Patient With CRC MetastasesAlthough the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.
Latest:
Effective Management and Prevention of Neratinib-Induced DiarrheaSafety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLCFerdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.
Latest:
Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated MelanomaFilip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.
Latest:
Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast CancerFilipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.
Latest:
Gathering Insights in Gastrointestinal Cancers From ESMO 2023: Dr PietrantonioOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Facilitating Intraperitoneal Chemotherapy CompletionFiona McCaughan on Nurses Facilitating Intraperitoneal Chemotherapy Completion
Latest:
Dr. Backes on Pelvic Exenteration Surgery in Gynecologic CancerFloor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.
Latest:
Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial CancerFloor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.
Latest:
Dr. Thompson on Sequencing Strategies in HER2+ Breast CancerForrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.
Latest:
Dr. Valdes-Albini Discusses Trials in HER2+ Breast CancerFrances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.
